Clinical Trials Browser

In Situ Hybridization, Fluorescence × Thoracic × Clear all

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Squamous Cell, Melanoma, Multiple Myeloma, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00899028 2017-04-20

Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants

Completed

689 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00907699 2014-07-24

Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on Clinical Trial CASE-2507

Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00989690 2013-08-12

Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

Phase 3 Unknown

275 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00900094 2012-02-07

IRB 2000-294

Completed

200 enrolled

BreastGastrointestinalGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Ovarian Epithelial, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

Clinical Trials

IT-TCP POS

Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants

Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on Clinical Trial CASE-2507

Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

IRB 2000-294